NIH PAR · NCI · R01
PAR-25-069: Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
- NOFO number
- PAR-25-069
- Type
- PAR
- Activity code
- R01
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Optional
- Posted
- Nov 18, 2024
- Opens
- Jan 5, 2025
- Expires
- Jan 8, 2027
PAR-25-069 due dates
No application due dates remain in the listed cycles. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 05, 2025 | March 05, 2025 * | Not Applicable | July 2025 | October 2025 | December 2025 |
| June 05, 2025 | July 05, 2025 * | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 05, 2025 | November 05, 2025 * | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 05, 2026 | March 05, 2026 * | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 05, 2026 | July 05, 2026 * | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 05, 2026 | November 05, 2026 * | Not Applicable | March 2027 | May 2027 | July 2027 |
What its predecessor PAR-23-279 funded
PAR-25-069 reissues PAR-23-279. Until awards appear under the new number, its funding history is the best guide to who wins under this program: 3 projects and $2.7M in FY2022–FY2026.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
3
Type 1 (new project) award records
NIH funding
$2.7M
Award dollars under PAR-23-279, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 1 | 1 | $693K |
| FY2026 | 3 | 2 | $2.0M |
Institutions with the most funding
- Yale University$1.4M · 1 project
- Univ of North Carolina Chapel Hill$1.3M · 2 projects
Funding institutes
- NCI$2.7M · 4
Activity codes funded
- R014 records
Most recent new awards
- Mitigating the Impact of Obesity on Endometrial Intraepithelial Neoplasia and Cancer with Incretin Mimetics (opens NIH RePORTER)
Univ of North Carolina Chapel Hill · 1R01CA300715-01 · NCI · Notice Jul 14, 2026
$658KR01
- Incretin Mimetics for Intercepting Obesity-Related Cancers: Effects and Underlying Mechanisms (opens NIH RePORTER)
Univ of North Carolina Chapel Hill · 1R01CA296816-01A1 · NCI · Notice Jun 23, 2026
$656KR01
- Targeting pancreatic endocrine-exocrine signaling in cancer development with incretin mimetics (opens NIH RePORTER)
Yale University · 1R01CA296916-01 · NCI · Notice Jan 23, 2025
$693KR01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-069. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy.
Award terms
- Application types allowed
- NewResubmission   The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are not limited but need to reflect the actual needs of the proposed project. 
- Project period
- The maximum project period is 5 years  NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious awards.  
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-23-279.
- Companion NOFOs: PAR-25-070.
Other open NOFOs for R01
- PAR-25-336Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)NCI · next due Nov 16, 2026
- PAR-27-072Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-337Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-338Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PAR-25-243Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PA-25-172Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.